BACKGROUND: Circulating tumor cells (CTCs) have been shown to be heterogeneous. Focusing on the epithelial-mesenchymal transition and perioperative kinetics, we evaluated CTCs with mesenchymal phenotypes as a potential prognostic biomarker for patients with gastric cancer. METHODS: Peripheral blood was collected from 54 patients with gastric cancer before surgery and at 1 week and 1 month after surgery. CTCs were enriched using density-gradient centrifugation and magnetic-activated cell sorting (negative selection). Cell suspensions were characterized by multi-immunofluorescence staining against cytokeratin and N-cadherin, and by 4',6'-diamidino-2-phenyldole staining. RESULTS: CTCs were detected in five patients (17%) with early cancer and 14 patients (56%) with advanced cancer (p < 0.05). In our system, N-cadherin, but not cytokeratin, was expressed in the CTCs of 90% (19/21) of patients. Postoperative recurrence was detected in 10 patients, all of whom had N-cadherin+/cytokeratin-/CD45- CTCs preoperatively. Regarding perioperative kinetics, we divided patients into three risk groups: a high-risk group, with one or more preoperative CTCs and increased CTCs postoperatively; an intermediate-risk group, with one or more preoperative CTCs and decreased CTCs postoperatively; and a low-risk group, with no preoperative CTCs. Recurrence rates were 57% (4/7), 33% (4/12), and 6% (2/35), respectively. The relapse-free survival rate was lower in patients at high risk versus those at intermediate or low risk, for all patients (p = 0.00024) and in patients with advanced cancer (p = 0.00103). CONCLUSIONS: N-cadherin is a highly useful marker to detect CTCs lacking cytokeratin, and the perioperative kinetics of CTC numbers is beneficial in risk stratification for survival in patients with gastric cancer.
BACKGROUND: Circulating tumor cells (CTCs) have been shown to be heterogeneous. Focusing on the epithelial-mesenchymal transition and perioperative kinetics, we evaluated CTCs with mesenchymal phenotypes as a potential prognostic biomarker for patients with gastric cancer. METHODS: Peripheral blood was collected from 54 patients with gastric cancer before surgery and at 1 week and 1 month after surgery. CTCs were enriched using density-gradient centrifugation and magnetic-activated cell sorting (negative selection). Cell suspensions were characterized by multi-immunofluorescence staining against cytokeratin and N-cadherin, and by 4',6'-diamidino-2-phenyldole staining. RESULTS: CTCs were detected in five patients (17%) with early cancer and 14 patients (56%) with advanced cancer (p < 0.05). In our system, N-cadherin, but not cytokeratin, was expressed in the CTCs of 90% (19/21) of patients. Postoperative recurrence was detected in 10 patients, all of whom had N-cadherin+/cytokeratin-/CD45- CTCs preoperatively. Regarding perioperative kinetics, we divided patients into three risk groups: a high-risk group, with one or more preoperative CTCs and increased CTCs postoperatively; an intermediate-risk group, with one or more preoperative CTCs and decreased CTCs postoperatively; and a low-risk group, with no preoperative CTCs. Recurrence rates were 57% (4/7), 33% (4/12), and 6% (2/35), respectively. The relapse-free survival rate was lower in patients at high risk versus those at intermediate or low risk, for all patients (p = 0.00024) and in patients with advanced cancer (p = 0.00103). CONCLUSIONS:N-cadherin is a highly useful marker to detect CTCs lacking cytokeratin, and the perioperative kinetics of CTC numbers is beneficial in risk stratification for survival in patients with gastric cancer.
Authors: Hadi Esmaeilsabzali; Timothy V Beischlag; Michael E Cox; Ash M Parameswaran; Edward J Park Journal: Biotechnol Adv Date: 2013-08-30 Impact factor: 14.227
Authors: Andrew J Armstrong; Matthew S Marengo; Sebastian Oltean; Gabor Kemeny; Rhonda L Bitting; James D Turnbull; Christina I Herold; Paul K Marcom; Daniel J George; Mariano A Garcia-Blanco Journal: Mol Cancer Res Date: 2011-06-10 Impact factor: 5.852
Authors: Ivonne Nel; Hideo A Baba; Judith Ertle; Frank Weber; Barbara Sitek; Martin Eisenacher; Helmut E Meyer; Joerg F Schlaak; Andreas-Claudius Hoffmann Journal: Transl Oncol Date: 2013-08-01 Impact factor: 4.243
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Min Yu; Aditya Bardia; Ben S Wittner; Shannon L Stott; Malgorzata E Smas; David T Ting; Steven J Isakoff; Jordan C Ciciliano; Marissa N Wells; Ajay M Shah; Kyle F Concannon; Maria C Donaldson; Lecia V Sequist; Elena Brachtel; Dennis Sgroi; Jose Baselga; Sridhar Ramaswamy; Mehmet Toner; Daniel A Haber; Shyamala Maheswaran Journal: Science Date: 2013-02-01 Impact factor: 47.728
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Patrick Weller; Ivonne Nel; Philipp Hassenkamp; Thomas Gauler; Anke Schlueter; Stephan Lang; Paulette Dountsop; Andreas-Claudius Hoffmann; Götz Lehnerdt Journal: PLoS One Date: 2014-12-05 Impact factor: 3.240
Authors: Priya Balasubramanian; James C Lang; Kris R Jatana; Brandon Miller; Enver Ozer; Mathew Old; David E Schuller; Amit Agrawal; Theodoros N Teknos; Thomas A Summers; Maryam B Lustberg; Maciej Zborowski; Jeffrey J Chalmers Journal: PLoS One Date: 2012-07-26 Impact factor: 3.240